Apollo Endosurgery (NASDAQ:APEN) is scheduled to release its earnings data before the market opens on Monday, March 18th. Analysts expect Apollo Endosurgery to post earnings of ($0.31) per share for the quarter.
APEN opened at $3.31 on Friday. Apollo Endosurgery has a one year low of $3.02 and a one year high of $9.65. The company has a market capitalization of $71.14 million, a P/E ratio of -1.65 and a beta of 0.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.81 and a current ratio of 2.42.
A number of research firms recently commented on APEN. Zacks Investment Research cut Apollo Endosurgery from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Northland Securities upgraded Apollo Endosurgery from an “under perform” rating to a “market perform” rating and set a $3.00 price objective on the stock in a report on Wednesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Apollo Endosurgery presently has a consensus rating of “Hold” and a consensus price target of $4.69.
In other Apollo Endosurgery news, major shareholder Stonepine Capital, L.P. sold 250,000 shares of the business’s stock in a transaction that occurred on Thursday, December 27th. The stock was sold at an average price of $3.00, for a total value of $750,000.00. Following the sale, the insider now owns 2,185,426 shares of the company’s stock, valued at $6,556,278. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 52.80% of the company’s stock.
A hedge fund recently raised its stake in Apollo Endosurgery stock. Dimensional Fund Advisors LP raised its position in Apollo Endosurgery Inc (NASDAQ:APEN) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,117 shares of the biotechnology company’s stock after purchasing an additional 6,551 shares during the quarter. Dimensional Fund Advisors LP owned 0.56% of Apollo Endosurgery worth $425,000 as of its most recent SEC filing. 39.30% of the stock is currently owned by institutional investors.
About Apollo Endosurgery
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgical and non-surgical bariatric and gastrointestinal procedures that are used by surgeons and gastroenterologists in various settings to provide interventional therapy to patients who suffer from obesity and various co-morbidities associated with obesity, as well as treat various other gastrointestinal conditions.
Read More: QQQ ETF
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.